Despite Durect Corp [DRRX]’s great opportunity, the stock is a bit overvalued

The price of Durect Corp (NASDAQ:DRRX) shares last traded on Wall Street rose 8.29% to $0.57.

Based on available information, 5 analysts follow Durect Corp (NASDAQ:DRRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $41.00 and a low of $5.00, we find $27.00. Given the previous closing price of $0.53, this indicates a potential upside of 4994.34 percent. DRRX stock price is now -78.24% away from the 50-day moving average and -86.42% away from the 200-day moving average. The market capitalization of the company currently stands at $15.75M.

Among analysts, 2 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $23.70 as their price target over the next twelve months.

With the price target of $7, Chardan Capital Markets recently initiated with Buy rating for Durect Corp (NASDAQ: DRRX).

Insiders disposed of 3,498 shares of company stock worth roughly $1993.86 over the past 1 year. A total of 1.39% of the company’s stock is owned by insiders.

A candlestick chart of Durect Corp (NASDAQ: DRRX) showed a price of $0.5500 on Thursday morning. During the past 12 months, Durect Corp has had a low of $0.51 and a high of $9.50. As of last week, the company has a debt-to-equity ratio of 4.15, a current ratio of 0.97, and a quick ratio of 0.92. The fifty day moving average price for DRRX is $2.6228 and a two-hundred day moving average price translates $4.2023 for the stock.

The latest earnings results from Durect Corp (NASDAQ: DRRX) was released for Jun, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.46, beating analysts’ expectations of -$0.51 by 0.05. This compares to -$0.51 EPS in the same period last year. The net profit margin was -185.87% and return on equity was -171.11% for DRRX. The company reported revenue of $2.08 million for the quarter, compared to $2.08 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.24 percent. For the current quarter, analysts expect DRRX to generate $2.97M in revenue.

Durect Corp(DRRX) Company Profile

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Related Posts